Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Succinylated gelatine: an alternative to hydroxyethyl starch for labelling leukocytes with 99mTc-HMPAO

Roca, Manela; Armero, Félixa; Jiménez, Ignacioa; Rodríguez-Gasén, Albaa; Díaz, Carmenb; Martín-Comín, Josepa

Nuclear Medicine Communications: August 2005 - Volume 26 - Issue 8 - p 749-752
doi: 10.1097/01.mnm.0000172741.36488.f7
ORIGINAL ARTICLES
Buy

Background Hydroxyethyl starch (HES) is the most used plasma expander in the sedimentation of the erythrocytes during the radiolabelling procedure for leukocytes in vitro.

Aim To evaluate the usefulness of succinylated gelatine (GEL), another colloidal plasma expander, as an alternative to HES in this process.

Methods Two identical blood samples were obtained from 30 patients referred to white blood cell scintigraphy. The first sample was used to label leukocytes with 99mTc-HMPAO using the routine procedure, with HES. The other sample was used to label leukocytes with 99mTc-HMPAO using the same procedure, with GEL. The cell concentration of the leukocyte–platelet-rich plasma (LPRP) achieved after blood sedimentation was analysed. Labelling efficiency was calculated and the eosin Y viability and red cell/leukocyte ratio were evaluated from the final labelled cell suspension.

Results Leukocytes and platelets recovered in LPRP were not statistically different between both HES and GEL samples (leukocytes: 8.10×103/μl±3.82 and 7.80×103/μl±3.47; platelets: 411×103/μl±182 and 406×103/μl±172, respectively). There were no significant differences between both agents on the labelling efficiency (HES: 80.3%±6.6%; GEL: 80.1%±6.3%), the eosin Y viability (HES: 99.2%±1.3%; GEL: 99.3%±1.1%) and the red cell/leukocyte ratio (HES: 1.21±0.7; GEL: 0.9±0.5).

Conclusion These results show that succinylated gelatine can be used instead of hydroxyethyl starch in the labelling of leukocytes with 99mTc-HMPAO.

aUnitat de Radiofarmàcia-Servei de Medicina Nuclear

bLaboratori Clínic de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

Correspondence to Dr Manuel Roca, Medicina Nuclear, Hospital Universitari de Bellvitge – IDIBELL, c/ Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain

Tel: +34 93 260 76 20; fax: +34 93 260 75 16;

e-mail: mrocae@csub.scs.es

Received 21 March 2005 Accepted 6 May 2005

© 2005 Lippincott Williams & Wilkins, Inc.